The CDMO Capacity Crunch With Discovery Labs' Audrey Greenberg and Iovance Biotherapeutics' Sumit Verma
Business Of Biotech
00:00
The Complexity of the Demand for Advanced Therapy Manufacturing
We're seeing companies that range in size from startup to large pharma that our environmental vector and cell therapy mRNA it's really across the board. There's incredible demand like Angela mentioned out there, and the ability to execute the product is incredibly important. Having a trusted partner that can execute and have the capabilities that you need in the timeline that makes sense is really what's about most importance. And so, we're really attacking the complexity and how we appeal to our client base.
Transcript
Play full episode
